The basic helix -loop -helix factor E2A plays an important role in the development of B and T lymphocytes. In addition, E2a has been implicated as a gene with tumor suppressor activity, since mice deficient for E2a succumb to T cell lymphomas. We have performed retroviral tagging in EmMyc transgenic mice to identify genes that contribute to lymphomagenesis. The EmMyc transgenic mouse is a well-established model of a common translocation in human B cell lymphomas. Analyses of the proviral insertion sites in the MuLVinduced lymphomas revealed that a number of T cell lymphomas carried proviral insertions in the promoter region of E2a. These proviral insertions yield hybrid viral-E2a mRNAs resulting in a marked rise in E2A protein levels. The proviral insertions in E2a were predominantly of clonal origin indicating that E2a insertions are early events in these T cell lymphomas. The primary oncogenic effect of E2A is likely to be associated with enhancement of transcription of the cMyc transgene via binding to the regulatory immunoglobulin enhancers. The results herein thus provide the first evidence that in a specific setting E2A overexpression can contribute to T-lymphomagenesis. This implies that E2a contains oncogenic features in addition to the previously described tumor suppressive properties.
Introduction
The E2A proteins belong to the highly conserved family of basic helix -loop -helix (bHLH) transcription factors. The E2a gene encodes two proteins E47 and E12. Both proteins contain identical transactivation domains, but a distinct dimerization domain enabling E47 to form homo-or heterodimers and E12 only heterodimers (Murre et al., 1989) . Upon homo-or heterodimerization with tissue-specific bHLHs, E2A binds the canonical E-box sequences in the promoter regions of their target genes and activate transcription. The tumorigenic potential of transactivation by E2A is illustrated by two distinct translocations t(1;19) and t(17;19) involving fusions of the transactivation domains of E2A to the DNA binding domains of the homeodomain gene, PBX, or the basic leucine zipper gene, HLF, causing pre-B acute lymphoid leukemia (ALL) and pro-B ALL in human, respectively (Kamps et al., 1990; Nourse et al., 1990; Inaba et al., 1992) .
Normally, E2A regulates important cellular processes such as B and T lymphoid development. In B cell development E2A drives differentiation of Bprogenitor cells towards pre-B and mature B cells (Bain et al., 1994; Zhuang et al., 1994) . Ectopic expression of E2A in a pre-T cell line or a macrophage cell line induces expression of the B cell specific genes Im, Rag1, l5, Ebf, Il7ra and Pax-5, which are involved in the early development of B cells (Schlissel et al., 1991; Kee and Murre, 1998) . The binding of E2A to the E boxes in the immunoglobulin gene regulatory regions is needed for maturation of B cells, since their development is blocked before rearrangement of the immunoglobulin genes in E2a knockout mice (Bain et al., 1994) . In addition to a block in B cell development, E2a-deficient mice show a defect in the differentiation of T cells. The development of T lymphoid cells is partially arrested at the CD4/CD8 double negative (DN) stage before rearrangement of the TCRb genes (Bain et al., 1999) . A similar block in T cell maturation is observed in mice expressing a dominant negative variant of HEB, a bHLH factor that is expressed in thymus and normally dimerizes with E2A (Barndt et al., 2000) . In this context, dominant negative HEB dimerizes with E2A, but is unable to bind DNA. Reinforced expression of a functional TCR in these mice did not rescue the defect, indicating that E2A-HEB heterodimers also play an important role after the rearrangement of the TCRb genes. E2A can also dimerize with HLH proteins that contain a dimerization domain but lack a DNA binding domain. These inhibitory domain (ID) proteins behave as endogenous dominant negative E2A proteins by preventing binding of E2A heterodimers to the E elements (Benezra et al., 1990) . In the absence of ID3, the maturation of CD4/ CD8 double positive (DP) T lymphocytes to CD4 or CD8 single positive (SP) T cells is blocked (Rivera et al., 2000) . This block is absent in mice deficient for both E2a and Id3 indicating that E2A can, under these circumstances, inhibit differentiation of T lymphocytes and underscores the need for a balanced expression of the bHLH and HLH proteins for normal T cell development.
Several observations have led to the conclusion that E2A can act as a tumor suppressor in T cell lymphomagenesis. Overexpression of E2A in a human T-acute lymphoblastic leukemia (T-ALL) inhibits cell cycle progression and induces apoptosis (Park et al., 1999) . In line with this, mice lacking E2a develop T cell lymphomas and re-expression of E2A in these tumors results in the induction of apoptosis (Bain et al., 1997; Yan et al., 1997; Engel and Murre, 1999) . Similarly, in NIH3T3 fibroblasts, overexpression of E2A causes a G1 arrest (Peverali et al., 1994) , whereas E2A can promote cell cycle progression in B cells (Zhao et al., 2001) .
Human leukemias are often the result of reciprocal translocations involving the immunogobulin-locus and an oncogene, where the presence of the immunoglobulin enhancers deregulates the expression of the fused oncogene (Kuppers and Dalla-Favera, 2001 ). The tumors arising from such translocations can be studied in mouse models in which the translocation has been introduced as a transoncogene (Adams et al., 1999) . We performed retroviral insertional mutagenesis in EmMyc mice, which express c-Myc under control of the immunoglobulin enhancers, to identify genes that contribute to lymphomagenesis. Identification of the retroviral insertion sites revealed that a substantial proportion of T cell lymphomas, but none of the B cell lymphomas, carried a provirus near the E2a gene. Characterization of these tumors showed that the proviral E2a insertions induce high levels of E2A. In addition, we present evidence that, in this experimental setting, the activation of E2a is an early event in T cell lymphomagenesis and is instrumental in enhancing cMyc transgene expression.
Results
The E2a locus is frequently mutated in EmMyc T cell lymphomas by proviral insertion
Neonates expressing the c-Myc transgene under control of the endogenous murine c-Myc proximal promoter and immunoglobulin heavy chain enhancers were infected with Moloney murine leukemia virus (M-MuLV). The mice succumbed to lymphomas with a median latency of 45 days. FACS analysis showed that the majority of mice developed lymphomas of the B cell lineage. However, 25% of the mice developed T cell lymphomas. These observations are in line with previously published results van Lohuizen et al., 1991) .
In order to identify genes that contribute to T cell lymphomagenesis in these mice, the genomic sequences flanking the provirus in the T cell lymphomas were isolated utilizing a splinkerette-based PCR amplification (Mikkers et al., 2002) . The amplified provirus flanking sequences were sequenced and compared to the EST, non-redundant and mouse genome databases at NCBI. BLAST searches revealed that two independent T cell lymphomas, 81 and 11, carried a proviral insertion in the same genomic region. This site was therefore designated a common proviral insertion site (CIS). A CIS is indicative of the oncogenic potential of a certain locus. This is based on robust statistical considerations of CISs (Mikkers et al., 2002) and supported by the oncogenic properties of all other previously identified common proviral target genes such as c-Myc and Pim1 (for review see Jonkers and Berns, 1996) . Subsequent sequence analysis of these proviral insertions showed that the proviruses had inserted upstream of, and in the same transcriptional orientation as, the E2a gene (Figure 1a) . To determine the frequency of proviral insertion at this locus, Southern blot analysis of 110 EmMyc tumors was performed using a 600 bps BstYI fragment upstream of E2a as a probe. A total of five independent EmMyc tumors, all of which showed a similar T cell specific marker profile (CD4 + CD8 + DP), carried a proviral insertion in the E2a locus (Figure 1b) . The finding that five of 27 T cell lymphomas and none of 83 B cell lymphomas carried proviral insertions in the E2a locus makes proviral insertions near E2a, at least in the EmMyc background, T cell exclusive (P=0.001, Fisher's exact test). Furthermore, these Southern analyses illustrated that the majority of E2a insertions are clonal in tumors that contain additional subclonal proviral insertions at other loci. This indicates that insertions in the E2a locus thus likely occurred early on in the tumorigenic process and, hence, these E2a insertions fulfil an important step in the selection process of these T cell lymphomas. Wild-type E2A is overexpressed in T cell lymphomas carrying E2a insertions
The incidence of T cell lymphomas in E2a 7/7 mice together with the potential of exogenously introduced E2A to induce apoptosis in E2a-deficient T cell lymphomas and human T-ALL cell lines has provided evidence for a tumor suppressor role for E2A in T cell lymphomagenesis (Bain et al., 1997; Yan et al., 1997; Engel and Murre, 1999; Park et al., 1999) . However, our observation of proviral insertions in the E2a promoter region in the same transcriptional orientation as E2a suggests that the provirus serves as an alternative promoter for E2a transcription (for review see Jonkers and Berns, 1996) . To address the question of whether the proviral insertions near E2a indeed altered E2A expression, E2a mRNA and protein levels in these tumors were determined. The E2a mRNA transcript levels were not consistently higher than those in T cell lymphomas lacking insertions near E2a (Figure 2a ). However, the protein levels of both E47 and E12 were increased markedly (Figure 2b ), indicating that not transcription initiation, but rather mRNA translation is altered as a consequence of the proviral insertions.
The size of E2A mRNA and protein appeared unaffected compared to the endogenous E2A in control lymphomas and MEL cells, indicating that the coding sequence was not affected by proviral insertions. In case of a proviral promoter insertion, transcription of the mutant mRNA normally starts from the CAP site in the 5' or 3' long terminal repeat (LTR) of the provirus (Jonkers and Berns, 1996) . To analyse the E2a transcripts in the tumors carrying insertions near E2a, mutant E2a cDNAs were generated by RT -PCR amplification using a virus-specific primer and an E2a-specific primer (Figure 3a) . Alignment of the genomic sequence 5' of the E2a gene with the sequence of the amplified cDNAs revealed that in all tumors the mutant E2a messenger starts in the 5' LTR of the provirus, is spliced from the splice donor site in the provirus, upstream of GAG, to a cryptic splice acceptor site in the 5' UTR of E2a, 57 nucleotides upstream of the ATG start (Figure 3b ). On the basis of the genomic sequence of the murine E2a locus and the rat E2a mRNA sequence, which is longer than the mouse E2a mRNA sequence in the NR database at NCBI, the mutant E2a RNA was calculated to be 97 bases longer and encodes an intact wild-type E2A protein. This altered 5' UTR of the E2a transcript is likely to increase the translation efficiency of the proviral E2a fusion transcript, since it is known that the translation efficiency of eukaryotic mRNAs depends on the secondary structures in the 5' UTR (Kochetov et al., 1998) .
Although this mutant E2a transcript is the most abundant one generated by the provirus, the simultaneous expression of dominant negative E2A splice variants cannot be formally excluded. Therefore, we analysed different T cell tumors for their E2A transactivation capacity. Transfection of 679, a T cell line without E2a insertions, and DKM81, one of our T-lymphomas carrying a clonal proviral insertion in the E2a gene, with an E2A responsive reporter plasmid in which the luciferase reporter gene is driven by six Em-elements showed that tumor DKM81 exhibited nearly a two-log enhanced transcription of the reporter gene (Figure 4 ). Ectopic expression of E47 increased the E2A-mediated transactivation in DKM81 even more. These results demonstrate that the T cell tumors carrying proviral insertions near E2a produce high levels of transactivating wild-type E2A, implying that E2A overexpression contributed to T cell lymphomagenesis in these tumors.
E2a overexpression is likely associated with an enhanced transcription of the immunoglobulin heavy chain enhancers controlled transgene in MuLV-induced T cell lymphomas
We have shown that E2A is overexpressed via proviral insertion in 5 EmMyc T cell lymphomas, but the question remained whether the insertions near E2a are exclusive for T cell lymphomas generated in the EmMyc background. If E2a would be a dominant oncogene in T cell lymphomagenesis, proviral insertions near E2a would also be selected for in MuLV-induced T lymphomas derived from a distinct background. Therefore, 39 MuLV-induced T cell lymphomas derived from H2K-Myc transgenic animals in which c-Myc expression is driven by the MHC class I H2K promoter, 30, 30 and 22 T cell lymphomas derived from EmPim1, EmBmi1 and EmGfi1 transgenic animals, respectively, and 123 wild-type T cell tumors were analysed for E2a promoter insertions. From this collection, only one T cell lymphoma carried a proviral insertion near E2a (not shown). It was a CD4 + T cell lymphoma derived from an EmPim1 transgenic mouse, and the proviral insertion was clonal. As in EmMyc transgenic mice, the expression of the Pim1 transgene in EmPim1 mice is under the control of immunoglobulin heavy chain enhancers. The exclusive presence of E2a promoter insertions in tumors with Em-driven transoncogenes excludes a role for E2a as a dominant oncogene. Together with the notion that E2a is known to induce transcription of the immunoglobulin chains via binding to their regulatory E boxes (Murre et al., 1989; Bain et al., 1993; Shen and Kadesch, 1995) it however suggests that E2a insertions exert their oncogenic effect through altered expression of the transgene. This would be in line with our observation that proviral activations of E2a are early events in tumor initiation rather than tumor progression, and also explain the E2a insertion in the EmPim1 tumor, since it is known that the oncogenic potential of Pim1 is strongly dose-dependent (Domen et al., 1993; van der Lugt et al., 1995; Allen et al., 1997) .
Unlike EmMyc B cells, transgenic T cells do normally not express the c-Myc transgene (Langdon et al., 1986; Alexander et al., 1987) , whereas upregulation of Myc, through either direct or indirect mechanisms, is invariably seen in MuLV-induced lymphomas (Berns et al., 1994) . In addition, it has been shown that EmMyc B cell lymphomas, both the spontaneous as well as the MuLV-induced tumors, have lost the endogenous c-Myc mRNA and only express the transgenic copy (Adams et al., 1985; van Lohuizen et al., 1991) . In line with this, high levels of the transgenic c-Myc mRNA were found in all tumors regardless of proviral insertions in the promoter of E2a (Figure 5a ). This observation suggests that proviral activation of E2a reflects one of the ways to augment c-Myc expression. Since proviral insertions near c-Myc are often found in MuLV-induced lymphomas, the most straightforward way to enhance MYC levels would be via proviral insertions in c-Myc, either the endogenous gene or transgene. Southern blot analysis of the EmMyc tumors for proviral insertions in c-Myc using a c-Myc cDNA probe showed that two T cell Figure 4 The overexpressed E2A protein is functionally active. T cell lines positive (DKM81) or negative (679) for proviral E2a insertions were transfected with an E2A-responsive luciferase reporter in the presence or absence of E47 and the luciferase activity was determined. Results represent the mean of three independent experiments (Figure 5b) . In order to test the notion that E2A can enhance expression of a gene regulated by the EmMyc promoter, the c-Myc coding region in the transgenic cassette was replaced with the luciferase gene (Figure 6a ). Cotransfection of EL-4 or 679 T cells with the Em-luciferase reporter and E47 expression plasmids showed that E47 enhances transcription of this specific reporter gene approximately twofold (P=0.001 and P=0.004, respectively). Although this is a relatively modest effect, it supports the view that proviral insertions near E2a in our tumor models act by upregulating expression of the transgene (Figure 6b ).
Discussion
The data presented here illustrate that the E2A basic helix -loop -helix factors need not necessarily to act exclusively as tumor suppressors in T cell lymphomagenesis, as has been proposed by studies in which E2a-deficient mice develop T cell lymphomas or in which ectopically introduced E2A induces apoptosis in T cell lymphomas (Bain et al., 1997; Yan et al., 1997; Engel and Murre, 1999; Park et al., 1999) . We show here that in MuLV-induced T cell lymphomas in EmMyc mice proviral insertions in the promoter region of E2a cause high levels of E2A protein, likely as a result of more efficient translation of the altered mRNA, a mechanism similar to the provirus-mediated overexpression of LCK in T lymphomas (Voronova et al., 1987) . In the EmMyc T cell lymphomas described here high E2A levels evidently trigger the development of T cell lymphomas by augmenting transgenic c-Myc levels. Since end-stage T cell lymphomas still express high levels of functional E2A, E2A is likely instrumental in maintaining high levels of MYC throughout the tumorigenic process. This is in accordance with the maintenance function of other genes implicated in tumor initiation (Felsher and Bishop, 1999; Fisher et al., 2001) . We can, however, not exclude the possibility that E2A confers an additional selective growth advantage on the T cell lymphomas, although this is unlikely in view of the fact that E2a activation was never found in tumors lacking an oncogene driven by an E2A responsive Em-promoter. Hence, whether E2A loss or E2A overexpression contributes to T lymphomagenesis depends on the experimental setting, underscoring the selective pressure imposed by the initial lesion on subsequent events in neoplastic transformation.
The ability of E2A to induce apoptosis in immature E2a-deficient and mature CD4 + T cell lymphomas seems contradictory to the E2A overexpression in CD4 + CD8 + T cell lymphomas observed in this study. The majority of T cell lymphomas isolated from the E2a knockout mice express, like the EmMyc lymphomas, high levels of MYC caused by amplifications of cMyc (Bain et al., 1994) . High MYC levels are known to induce apoptosis by either a P53 dependent or independent pathway (Hsu et al., 1995; Sakamuro et al., 1995) . A potential explanation for this observation would be that in E2a-deficient lymphomas the MYCinduced apoptosis is inhibited by the absence of E2A, positioning E2A downstream of MYC-induced apoptosis. In order to yield EmMyc lymphomas expressing high levels of both MYC and E2A the apoptosis induced by these proteins needs to be impaired. To prevent apoptosis this event has to occur prior to E2a and concomitant Myc activation, since only genetic alterations that inhibit the E2A-and MYC-induced apoptosis would allow expansion of cells carrying a proviral insertion near E2a.
The levels of E2A, predominantly expressed as E47, are high in late DN (DN3 and DN4) and early DP T lymphocytes during positive selection of T cells, and low during transition of DP to SP T lymphocytes and in mature T cells (Bain et al., 1999; Engel et al., 2001) . It is therefore remarkable that none of the EmMyc T cell lymphomas were of the DN3, DN4 or early DP immature phenotype. This suggests that transactivation of the EmMyc transgene by endogenous E2A is not very efficient in the early stages of T cell development, or alternatively, T cells in this differentiation window do not serve as a suitable cell population to acquire , which do not express E2A, were co-transfected with E47 expression and Em-luciferase plasmids and luciferase activity was measured. The data represent the mean of four independent experiments. *P=0.001 **P=0.004 (ANOVA) subsequent hits driving transformation. In addition, we never identified proviral insertions near E2a in MuLVinduced Em-Myc B cell lymphomas, although E2A can upregulate an Em-driven transgene. This is likely explained by the lack of the requirement to activate c-Myc in these B cell lymphomas in contrast to the described situation in Em-Myc T cell lymphomas. cMyc is expressed at very high levels in the B-lymphoid compartment of the Em-Myc mice (Figure 5 ), probably as a result of high endogenous E47 levels (Figure 3) , thereby diminishing the selective advantage provided by extra c-Myc.
Tumorigenesis is a continuous selection process involving step-wise alterations affecting the expression of oncogenes and tumor suppressor genes ultimately leading to a full-blown tumor. In MuLV-induced tumors, only the proviral insertions that confer a growth advantage to a cell will be selected for during lymphomagenesis. This means that every tumor population contains multiple proviral insertions of which the most clonal ones represent the most dominant, or early, selection events. In addition, two events reflecting the same contribution to tumorigenesis will hardly ever be found in one, monoclonal, tumor population. Although a number of tumors carrying E2a insertions consisted of an oligoclonal population of tumor cells, the E2a insertions in these tumors were clonal indicating that E2A overexpression conferred a significant and most likely early event in these tumors. Since only events collaborating with E2A in lymphomagenesis will be present in tumors carrying a proviral insertion near E2a, the assignment of E2A to a group of genes with overlapping functions, and therefore designated a complementation group, can be addressed. Analysis of the lymphomas carrying E2a insertions for mutations collaborating with E2A and the subsequent assignment of E2A to a complementation group might provide more insight in the apoptotic and oncogenic signaling pathways of E2A. Approximately 40% of the EmMyc T cell lymphomas generated by MuLV infection carry proviral insertions affecting Pim1, a serine/threonine kinase (van Lohuizen et al. 1991) and/or Gfi1, a protein with characteristics of a transcriptional repressor (Gilks et al., 1993; Zweidler-Mckay et al., 1996; Scheijen et al., 1997) . In the EmMyc T cell lymphomas carrying E2a insertions, proviral insertions near Pim1 (including clonal), but no insertions affecting Gfi1 were found (P=0.06 Fisher's exact test). Consistent with this, proviral insertions near E2a were lacking in 22 EmGfi1 T cell lymphomas. Besides the absence of E2a insertions in EmGfi1 T cell lymphomas, E2a insertions have not been found in 30 T cell lymphomas derived from EmBmi1 mice. Proviral insertions near Gfi1 are rarely found together with insertions affecting Bmi1, a transcriptional repressor of the p16
Ink4a and p19
Arf tumor suppressor genes (Jacobs et al., 1999a) , suggesting that Gfi1 and Bmi1 exhibit a partially overlapping function with respect to their cooperation with Myc (Scheijen et al., 1997) . The main oncogenic effect of Bmi1 is inhibition of the MYC-induced apoptosis, explaining the strong collaboration of Bmi1 with c-Myc in lymphomagenesis (Jacobs et al., 1999b) . E2A clearly does not fit in this category. Proviral insertions near E2a likely can only persist in a cell that has already acquired an oncogenic event counteracting the E2A-mediated apoptosis. Apparently, the Gfi1/Bmi1 complementation group does not fulfill these requirements. This is supported by the identification of a clonal proviral insertion enhancing the expression of Bcl2l, a BCL-2 family member, in a tumor that carries an E2a insertion (not shown).
The identification of E2a as a gene activated by proviral insertions in 18% of the EmMyc T cell lymphomas has revealed an unexpected new role of E2a in T cell lymphomagenesis. In addition, the prime oncogenic effect mediated by high levels of E2A, namely enhancement of expression of a transoncogene, shows the feasibility of an in vivo genetic screen to identify transcriptional activators of genes. Furthermore, our data emphasize the importance of the nature of initiating mutations in dictating selection of subsequent lesions required for tumor progression. Interestingly, this fits well with recent observations showing that the expression profiles of relatively early tumor lesions already predict tumor characteristics that are thought to result from later occurring genetic alterations such as the capacity of tumors to metastasize (van 't Veer et al., 2002) . Our observations support the view that this might be rule rather than exception.
Materials and methods

Transgenic mice, tumor induction and cell type analysis
EmMyc (Adams et al., 1985; van Lohuizen et al., 1991) , H2K-Myc ), EmPim1 (van Lohuizen et al., 1989 , EmBmi1 (Alkema et al., 1995) and EmGfi1 (Scheijen et al., personal communication) neonates were infected with 1.10 5 infectious units of M-MuLV. Moribund mice were sacrificed and lymphomas were isolated. Lymphoma cells were disaggregated and analysed by FACS using PEconjugated anti-CD4 (YTS 191.1) (Caltag), FiTC-conjugated anti-CD8 (53-6.7) (Pharmingen) and biotinylated anti-B220 (RA3-6B2) (Pharmingen) antibodies. Bound biotinylated antibodies were detected with Streptavidin-PerCP (Becton Dickinson). Staining was analysed on a FACScan flow cytometer (Becton Dickinson).
Splinkerette-based amplification of proviral insertion sites
Briefly, splinkerette-adaptors were ligated to BstYI restricted genomic tumor DNA (Mikkers et al., 2002) . The splinkerrette/genomic DNA fragments were amplified using 32 Plabeled virus-specific and splinkerrette-specific primers. Fragments were separated on a 3.5% polyacrylamide gel and excised. The excised fragments were re-amplified with a nested primer set, again separated on a 3.5% PAA gel and excised. Re-amplification with the same primers yielded ready-to-sequence products. BigDye sequence reactions were performed according the manufacturer (Perkin Elmer) and analysed on an ABI377 automated sequencer (Perkin Elmer). The sequences were processed using Sequencher3.1.1 TM and
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Southern and Northern blotting
Tumor DNA was isolated as previously described (van der Putten et al., 1979) . For Southern blot analyses, tumor DNA (10 mg) was digested with Asp718 and separated on a 0.6% agarose gel. DNA was transferred to Hybond-N+ membranes (Amersham) under alkaline conditions. A genomic BstYI fragment 5' of the E2a gene, isolated from the mouse PAC library RPCI21 (purchased from P de Jong, Roswell Park) and full-length mouse c-Myc cDNA were used as probes. Total tumor RNA was isolated by homogenization of tumors in Trizol (Gibco-BRL) according to the manufacturer. Tumor RNA (10 mg) was separated on a 1% formaldehyde gel and subsequently transferred to Hybond-N membranes (Amersham). Full length hE47 (kind gift of C Murre, UCSD), mouse c-Myc and hGAPDH cDNAs were used as probes.
Protein isolation and Western blotting
Total protein was extracted from the tumors as described previously (Bain et al., 1999) . Total proteins (25 mg) were separated on 9% SDS-polyacrylamide gels and transferred to nitocellulose membranes (Schleicher and Schuell). Blots were incubated with monoclonal antibodies specific for E47 (32.1, Pharmingen,) E12 (382.6, Pharmingen,) or GSK3 (Transduction laboratories). Proteins were visualized with HRP-labeled secondary antibodies (Dako) and ECL (Amersham).
RT -PCR and genomic PCR on tumor mRNA
Tumor-specific cDNA was generated by incubation of DNase-treated RNA (5 mg) with 2U Superscript II reverse transcriptase (Gibco BRL) and 75 ng of random hexamers (Promega) for 50' at 428C. After RNase H treatment of the cDNA, the virus-specific E2a cDNA was amplified with the primers MuLV-U5: 5'-CTCTTGCAGTTGCATCCGACTT-GTG-3' and E2a 5': 5'-GCACCTTCGTGTATGTCCG-3'. Using the same primers, genomic DNA was amplified from tumors 11 and 23. DNA sequences were analysed using BigDye Terminator chemistry (Perkin Elmer) on an automated ABI377 Sequencer (Perkin Elmer).
Luciferase reporter assay
In order to precisely retain the c-Myc intron 1-exon 2 boundaries in pA17-LUC, a NcoI site was introduced at the c-Myc start by PCR (CGATG?CCATG). The primers were as follows: saMycXbaI 5'-GCTGGATAACTCTAGACTT-GC-3' and saMycNcoI 5'-TTTTTCCATGGTCGTGGCTGT-CTGC-3'. Using this linker, the c-Myc coding sequences in pA17 (Adams et al., 1985) were replaced with the luciferase gene, containing a NcoI site within the ATG coding nucleotides, by insertion into the XbaI site in intron 1, 90 bps upstream of c-Myc exon 2, and the KpnI site downstream of c-Myc. Murine EL-4 cells have been described elsewhere (Gorer, 1950) . The murine 679 T cell line was derived from an EmPim1 CD4 + CD8 + T cell lymphoma. Tumor cells were cultured in IMEM (Gibco-BRL) supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 U/ml) and 50 mM b-mercaptoethanol. Exponentially growing cells were electroporated in 0.5 ml RT culture medium (1 -2610 7 cells/ml) using a Genepulser II (BioRad) at 260 V and 950 mF. E2A activity was checked by transfection of the T cells with (E2+E5)6x-Luc+ (15 mg) (kind gift of C Murre, UCSD), containing the luciferase gene under control of 6 mE5+E2 boxes and the LBK-AP minimal promoter, CMV-bGal (15 mg) and pcDNA3-hE47 (15 mg) or pcDNA3 (15 mg). For the Em-transgene reporter assay, cells were transfected with pA17-Luc+ (15 mg), CMV-bGal (15 mg) and either pcDNA3-hE47 (kind gift of C Murre, UCSD) or pcDNA3 (15 mg). Transfection efficiencies were *30% as determined by FACS analysis of CMV -GFP transfected cells. Transfected cells were lysed 24 h after transfection in reporter lysis buffer (Promega) and Luciferase activity was determined using Luciferase Assay Reagent (Promega) according to the manufacturer's directions. Cell extracts were normalized with a standard b-galactosidase assay.
